Empress Therapeutics
+7
Mar 31, 2026
•
8 min read
Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates
+6
Dec 16, 2025
6 min read
A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.
